Immunotherapy with oral, heat-killed, Mycobacterium vaccae in patients with moderate to advanced pulmonary tuberculosis

Immunotherapy

Volumn 2, Issue 2, 2010, Pages 159-169

  Dlugovitzky, Diana ^a   Notario, Rodolfo ^a   Martinel Lamas, Diego ^a   Fiorenza, Gladys ^a   Farroni, Miguel ^b   Bogue, Christina ^b   Stanford, Cynthia ^c   Stanford, John ^c  

^a UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^b Hospital I Carrasco   (Argentina)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Immunological investigation; Immunotherapy; Mycobacterium vaccae; Oral capsule; Pulmonary tuberculosis

Indexed keywords

ETHAMBUTOL; GAMMA INTERFERON; INTERLEUKIN 10; ISONIAZID; PLACEBO; PROBIOTIC AGENT; PYRAZINAMIDE; RIFAMPICIN; SRL 172; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BACTERIAL VACCINE; CULTURE MEDIUM; INACTIVATED VACCINE;

ADOLESCENT; ADULT; ARGENTINA; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GOOD CLINICAL PRACTICE; HUMAN; IMMUNOTHERAPY; LUNG TUBERCULOSIS; MALE; MONONUCLEAR CELL; MYCOBACTERIUM VACCAE; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHORT COURSE THERAPY; SPUTUM ANALYSIS; THORAX RADIOGRAPHY; ACTIVE IMMUNIZATION; BIOSYNTHESIS; CELL CULTURE; CHEMISTRY; CLINICAL TRIAL; CULTURE MEDIUM; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; MYCOBACTERIUM; ORAL DRUG ADMINISTRATION; SECRETION (PROCESS); TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BACTERIAL VACCINES; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; INJECTIONS, INTRADERMAL; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYCOBACTERIUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 77953452998     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.09.90     Document Type: Article

References (40)

1. Hughes ACC: Streptomycin in tuberculosis. In: Modern Practice in Tuberculosis. (Chapter 17, Volume 1). Holmes Sellars T, Livingstone JL (Eds). Butterworth and Company, London, UK, 301-314 (1952).
2. Borgdorff MW, Floyd K, Broekmans JF: Interventions to reduce tuberculosis mortality and transmission in low-and middle-income countries. Bull. World Health Organ. 80(3), 217-227 (2002).
3. World Health Organization (WHO): The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance 2000. WHO/CDC/TB/ 200.278/. Geneva, Switzerland (2000).
4. World Health Organization (WHO): Report of the meeting of the WHO Global Task Force on XDR-TB. Geneva, Switzerland, 9-10 October 2006.
5. World Health Organization (WHO): The global MDR-TB and XDR-TB response plan 2007-2008. WHO/HTM/ TB/2007.387 (2009).
6. World Health Organization (WHO): Report of the expert consultation on immunotherapeutic interventions for tuberculosis. WHO/TDR/IRM/07.1 (2007).
7. Churchyard MD, Kaplan G, Fallows D et al.: Advances in immunotherapy for tuberculosis. Clin. Chest Med. 30, 769-782 (2009)
8. Bottasso OA, Bay ML Besedovsky H, del Rey A: Immuno-endocrine alterations during human tuberculosis as an integrated view of disease pathology. Neuroimmunomodulation 16, 68-77 (2009).
9. Rook GA: Th2 cytokines in susceptibility to tuberculosis. Curr. Mol. Med. 7(3), 327-337 (2007).
10. Stanford JL, Stanford CA, Grange JM: Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front. Biosci. 9, 1701-1719 (2004).
11. Corlan E, Marica C, Macavei C et al.: Immunotherapy with Mycobacterium vaccae. 1. In the treatment of newly diagnosed pulmonary tuberculosis in Romania. Respir. Med. 91, 13-19 (1997).
12. Bahr GM, Shaaban MA, Gabriel M et al.: Improved immunotherapy for pulmonary tuberculosis with Mycobacterium vaccae. Tubercle 71, 259-266 (1990).
13. Onyebujoh P, Abdulmumini T, Robinson S et al.: Immunotherapy for tuberculosis in African conditions. Respir. Med. 89, 199-207 (1995).
14. Dlugovitzky D, Bottasso O, Dominino JC et al.: Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172). Respir. Med. 93, 557-562 (1999).
15. Dlugovitzky D, Fiorenza G, Farroni M et al.: Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis. Respir. Med. 100, 1079-1087 (2006).
16. Dlugovitzky D, Fiorenza G, Martinel-Lamas D et al.: The potential for immunotherapy with heat-killed Mycobacterium vaccae in respiratory medicine. Immunotherapy 1(6), 933-947 (2009).
17. Johnson JL, Kamya RM, Okwera A et al.: Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodefciency virus-infected ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration. J. Infect. Dis. 181, 1304-1312 (2000).
18. Durban Immunotherapy Trial Group: Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Lancet 354, 116-119 (1999).
19. Stanford JL, Stanford CA, Grange JM: Environmental echoes. Sci. Prog. 84, 105-124 (2001).
20. Farid R, Etemadi A, Mehvar M et al.: Mycobacterium vaccae immunotherapy in the treatment of multi-drug-resistant tuberculosis: a preliminary report. Iranian J. Med. Sci. 19, 37-39 (1994).
21. Corlan E, Marica C, Macavei C et al.: Immunotherapy with Mycobacterium vaccae. 2. In the treatment of chronic or relapsed tuberculosis in Romania. Respir. Med. 91, 21-29 (1997).
22. Stanford JL, Stanford CA, Grange JM et al.: Does immunotherapy with heat-killed Mycobacterium vaccae offer hope for the treatment of multi-drug-resistant pulmonary tuberculosis? Respir. Med. 95, 444-447 (2001).
23. Reid S, Van Niekerk AA: Injection risks and HIV transmission in the Republic of South Africa. Int. J. STD AIDS 20(12), 816-819 (2009).
24. Stainsby KJ: Development of a tuberculosis vaccine for the badger. PhD Thesis. University of London (1989).
25. Zuany-Amorim C, Sawicka E, Manlius C et al.: Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specifc regulatory T-cells. Nat. Med. 8, 625-629 (2002).
26. Hernandez-Pando R, Pavon L, Arriaga K et al.: Pathogenesis of tuberculosis exposed to low and high doses of an environmental mycobacterial saprophyte before infection. Infect. Immun. 65(8), 3317-3327 (1997).
27. Hernandez-Pando R, Aguilar D, Orozco H et al.: Orally administered Mycobacterium vaccae modulates expression of immunoregulatory molecules in Balb-c mice with pulmonary tuberculosis. Clin. Vaccine Immunol. 15(11), 1730-1736 (2008).
28. Stanford JL, Grange JM: The meaning and structure of species as applied to mycobacteria. Tubercle 55, 143-152 (1974).
29. Stanford J, Stanford C, Stansby G et al.: The common mycobacterial antigens and their importance in the treatment of disease. Curr. Pharm. Des. 15, 1248-1260 (2009).
30. Matzinger P: Tolerance, danger, and the extended family. Ann. Rev. Immunol. 12, 991-1045 (1994).
31. Cohen IR, Young DB: Autoimmunity, microbial immunity and the immunological homunculus (Immunculus). Immunol. Today 2, 264-271 (1991).
32. Gebert A, Rothkotter HJ, Pabst R: M cells in Peyer's patches in the intestine. Int. Rev. Cytol. 167, 91-159 (1996).
33. Maraveyas A, Baban B, Kennard D et al.: Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood leucocytes. Ann. Oncol. 10, 817-824 (1999).
34. Stanford JL, Stanford CA, O'Brien M, Grange JM: Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur. J. Cancer 44, 224-227 (2008).
35. Patel PM, Sim S, O'Donnell DO et al.: An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer. Eur. J. Cancer 44, 216-223 (2008).
36. von Reyn CF, Marsh BJ, Waddell RD et al.: Cellular immune responses to mycobacteria in healthy and human immunodefciency virus positive subjects in the United States after a fve dose schedule of Mycobacterium vaccae vaccine. Clin. Infect. Dis. 27, 1517-1520 (1998).
37. Waddell RD, Chintu C, Lein AD et al.: Safety and immunogenicity of a fve-dose series of inactivated Mycobacterium vaccae vaccine for the prevention of HIV associated tuberculosis. Clin. Infect. Dis. 30(Suppl. 3), S309-S315 (2000).
38. Vuola JM, Ristola MA, Cole B et al.: Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. AIDS 17, 2351-2355 (2003).
39. Mwinga A, Nunn A, Ngwira B et al.: Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised, placebo-controlled trial. Lancet 360, 1050-1055 (2002).
40. Von Reyn CF, Mtei L, Arbeit RD et al.: Prevention of tuberculosis in BCG-primed, HIV-infected adults boosted with an inactivated whole cell mycobacterial vaccine. AIDS (2009) (In press).